Research and Policy CSR News

"AIDS Won't Stop for COVID-19": Meet 3 Inspiring Women Who Are as Committed as Ever to Making HIV History

Summary: 

As the International Aids Society Conference kicks off virtually this year, we sat down with three attendees, including activist and actress Laverne Cox, to talk about their groundbreaking work with HIV/AIDS in the midst of a global pandemic.

Blog

As the International Aids Society Conference kicks off virtually this year, we sat down with three attendees, including activist and actress Laverne Cox, to talk about their groundbreaking work with HIV/AIDS in the midst of a global pandemic.

Increasing Diversity in Clinical Trials: A Collaboration with Tufts Center for the Study of Drug Development

Article

To effectively support the goal of access for all citizens, we must consider all citizens. But delivering on that goal takes a commitment to understanding deeply who patients are, their needs, and how we can best support positive health outcomes. We need to start at the beginning and build into every decision we make and step we take the diverse socio economic and individual health considerations of each person we encounter.

#BacktheFrontline: Joe Wolk, Executive Vice President, Chief Financial Officer, Johnson & Johnson

Multimedia with summary

Accelerated innovation. Resources in the hands of health workers. Profit returned to the frontline.

Learn more about how we #BackTheFrontline by investing in innovators developing scalable solutions to COVID-19 from Johnson & Johnson Impact Ventures Chair Joe Wolk.

Follow along with us on @JNJGlobalHealth on Twitter and/or Instagram to hear from our leaders, employees and partners around the world about how YOU can meaningfully contribute.

Johnson & Johnson Announces European Commission Approval for Janssen's Preventive Ebola Vaccine

Summary: 
This marks the first major regulatory approval of a vaccine developed by Janssen

 

The Ebola vaccine regimen leverages Janssen’s AdVac® technology, plus Bavarian Nordic’s established MVA-BN® technology

 

Janssen’s AdVac® technology is also being used to develop a vaccine candidate to prevent COVID-19
Press Release
This marks the first major regulatory approval of a vaccine developed by Janssen

 

The Ebola vaccine regimen leverages Janssen’s AdVac® technology, plus Bavarian Nordic’s established MVA-BN® technology

 

Janssen’s AdVac® technology is also being used to develop a vaccine candidate to prevent COVID-19

Following Emergency Pandemic Response, the Tomorrow Rising Fund by the Schneider Electric Foundation Focuses Support on Recovery and Resiliency

Summary: 
  • Schneider Electric Foundation launched the Tomorrow Rising Fund to help vulnerable communities respond, recover and become more resilient in the wake of Covid-19
  • Schneider Electric’s people and partners across +60 countries have joined in by fundraising and volunteering to contribute to 65 projects which benefit +800,000 people
  • Following the initial emergency response, the fund continues to support education and professional training to secure the best future for young people and their communities
Press Release
  • Schneider Electric Foundation launched the Tomorrow Rising Fund to help vulnerable communities respond, recover and become more resilient in the wake of Covid-19
  • Schneider Electric’s people and partners across +60 countries have joined in by fundraising and volunteering to contribute to 65 projects which benefit +800,000 people
  • Following the initial emergency response, the fund continues to support education and professional training to secure the best future for young people and their communities

In Praise of Paper Ballots

Blog

As we enter into the 2020 election season, the way in which we participate has the potential to be impacted. From concerns around vote hacking to the fear of exposure to COVID-19, states are under increased scrutiny about how they will handle this year’s election. There is one thing that provides a good solution for both concerns – paper.

The Security of Paper Ballots

An Open Letter from Daniel O'Day, Chairman & CEO, Gilead Sciences

Blog

After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19 in August. If the trials are successful, this could represent important progress. Remdesivir, our investigational antiviral medicine, is currently given to patients intravenously through daily infusions in the hospital.

Cancer Immunotherapy Awareness Month™ at Alkermes

Multimedia with summary

Along with the Society for Immunotherapy of Cancer we strive for a future #Immune2Cancer because to our team, cancer immunotherapy research is personal. Our scientists are researching potential, new cancer treatment options for our loved ones and yours.

About Alkermes

A Human Rights-Based Approach to COVID-19 Decision-Making

Blog

By: Ouida Chichester, Associate Director, BSR; Rosa Kusbiantoro, Associate Director, BSR; Salah Husseini, Associate Director, Human Rights, BSR; Jenny Vaughan, Human Rights Director, BSR; and

People Feel Unsafe Using Public Restrooms with Air Dryers, New Study Finds

Summary: 

COVID-19 is shaping new attitudes and behaviors among people, especially a growing awareness of health risks associated with hygiene in public spaces. According to a new international study from Tork®, an Essity brand, nearly eight out of ten people surveyed in North America feel more unsafe going to facilities with unhygienic public restrooms today than before the pandemic - and 33% of these respondents say they feel unsafe entering a restroom equipped with air dryers.

Press Release

COVID-19 is shaping new attitudes and behaviors among people, especially a growing awareness of health risks associated with hygiene in public spaces. According to a new international study from Tork®, an Essity brand, nearly eight out of ten people surveyed in North America feel more unsafe going to facilities with unhygienic public restrooms today than before the pandemic - and 33% of these respondents say they feel unsafe entering a restroom equipped with air dryers.

Pages

Subscribe to Research and Policy